ScreenerHero
NBIXNeurocrine Biosciences, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · neurocrine.com
153.54USD-1.29%Mkt Cap: 15.81B $P/E: 22.77

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products i…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD
ALM
Almirall, S.A.
$2.46BUSDP/E 37.1

Key Statistics

Company
Market Cap15.81B $
Enterprise Value15.62B $
Revenue (TTM)3.37B $
Gross Profit2.81B $
Net Income (TTM)478.60M $
Revenue/Share33.66 USD
Last Price153.54 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS64125C1099
Valuation
P/E (Trailing)22.77
P/E (Forward)12.79
PEG0.46
EV/EBITDA17.10
EV/Revenue4.63
P/S4.61
P/B4.21
EPS (TTM)6.73
EPS (Forward)11.95
52W Range
122.1449% of range186.12
52W High186.12 USD
52W Low122.14 USD
Profitability
Gross Margin98.18%
Oper. Margin22.19%
EBITDA Margin27.07%
Profit Margin16.73%
ROE14.71%
ROA10.33%
Growth
Revenue Growth39.50%
Earnings Growth31.10%
Cash Flow & Leverage
Operating CF782.70M $
CapEx (TTM)34.00M $
FCF Margin18.92%
FCF Yield4.04%
Net Debt71.80M $
Net Debt/EBITDA0.08
Balance Sheet
Debt/Equity0.13
Current Ratio1.87
Quick Ratio1.46
Book Value/Sh36.35 USD
Cash/Share3.835 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateDec 29, 1995
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)211.57 USD
Upside (mean)+37.8%
Target Range165.00 USD – 249.00 USD
$165.00+37.8% to mean$249.00
# Analysts27
Ownership
Shares Out.101.65M
Float100.39M
Insiders1.06%
Institutions102.79%
Short Interest
Short Ratio3.4d
Short % Float5.61%
Short % Out.4.32%
Shares Short4.39M
Short (prev mo.)5.53M
Technical
SMA 50167.10 (-8.1%)
SMA 200147.11 (+4.4%)
Beta0.39
S&P 52W Chg18.16%
Avg Vol (30d)1.31M
Avg Vol (10d)1.24M
Technical Indicators
RSI (14)39.4
MACD-4.3561
MACD Signal-2.5328
MACD Hist.-1.8233
BB Upper187.05 USD
BB Middle166.44 USD
BB Lower145.84 USD
BB Width24.75%
ATR (14)5.364 USD
Vol Ratio (20d)0.76x